Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 10,000 Shares of Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total value of $1,398,900.00. Following the completion of the transaction, the chief executive officer owned 556,698 shares of the company’s stock, valued at $77,876,483.22. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Daniel Patrick O’day also recently made the following trade(s):

• On Friday, January 23rd, Daniel Patrick O’day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $135.00, for a total value of $15,611,400.00.
• On Monday, December 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $124.83, for a total value of $1,248,300.00.
• On Friday, November 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $126.54, for a total value of $1,265,400.00.

Gilead Sciences Trading Down 0.1%

Shares of NASDAQ:GILD traded down $0.17 during trading on Thursday, reaching $139.55. 7,147,792 shares of the company traded hands, compared to its average volume of 7,661,948. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $141.71. The firm has a market capitalization of $173.14 billion, a price-to-earnings ratio of 21.64, a P/E/G ratio of 0.74 and a beta of 0.33. The business’s fifty day moving average is $124.76 and its 200-day moving average is $119.24.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $2.02 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a research report on Monday, December 29th. Wolfe Research lifted their price objective on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday. Truist Financial upped their target price on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Finally, Daiwa Capital Markets upped their price target on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $135.56.

Institutional Investors Weigh In On Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the stock. Personal CFO Solutions LLC boosted its stake in Gilead Sciences by 1.7% in the 4th quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after purchasing an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC raised its holdings in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after buying an additional 76 shares during the last quarter. SOA Wealth Advisors LLC. raised its holdings in Gilead Sciences by 8.7% in the fourth quarter. SOA Wealth Advisors LLC. now owns 1,016 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 81 shares during the last quarter. Trivium Point Advisory LLC lifted its stake in shares of Gilead Sciences by 1.1% in the third quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock worth $813,000 after buying an additional 83 shares in the last quarter. Finally, Greatmark Investment Partners Inc. grew its holdings in shares of Gilead Sciences by 0.3% during the fourth quarter. Greatmark Investment Partners Inc. now owns 29,200 shares of the biopharmaceutical company’s stock valued at $3,584,000 after buying an additional 83 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.